Endothelial Cell Specific Molecule-1 (ESM-1): a Novel Biomarker for ARDS Endothelial Injury
1 other identifier
observational
70
1 country
1
Brief Summary
To observe the changes of plasma ESM-1 levels in patients with ARDS, and to explore its clinical significance.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Nov 2017
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 25, 2017
CompletedFirst Posted
Study publicly available on registry
September 28, 2017
CompletedStudy Start
First participant enrolled
November 1, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 20, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
February 20, 2018
CompletedNovember 1, 2017
September 1, 2017
2 months
September 25, 2017
October 30, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
mortality
28-day
Study Arms (2)
ESM-1<5ng/ml
ESM-1≥5ng/ml
Eligibility Criteria
Population admitted to ICU of Zhongda hospital ，diagnosed of ARDS
You may qualify if:
- Patients admitted to ICU diagnosed of ARDS (Berlin definition）in 48h
- Patients age between 18 years old and 80 years.
You may not qualify if:
- Pregnant women,
- Patients with malignant tumor,
- Immunosuppression or immunocompromised patients.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Jingyuan,Xulead
Study Sites (1)
Nanjing Zhongda Hospital, School of Medicine, Southeast University
Nanjing, Jiangsu, 210009, China
Study Officials
- STUDY CHAIR
Haibo qiu
Zhong-Da Hospital, School of Medicine, Southeast University,
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- chief doctor
Study Record Dates
First Submitted
September 25, 2017
First Posted
September 28, 2017
Study Start
November 1, 2017
Primary Completion
December 20, 2017
Study Completion
February 20, 2018
Last Updated
November 1, 2017
Record last verified: 2017-09
Data Sharing
- IPD Sharing
- Will not share